Equities research analysts expect Nightstar Therapeutics PLC (NASDAQ:NITE) to report earnings of ($0.39) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Nightstar Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.33). The business is expected to issue its next quarterly earnings results on Monday, November 12th.
On average, analysts expect that Nightstar Therapeutics will report full-year earnings of ($1.59) per share for the current year, with EPS estimates ranging from ($1.77) to ($1.42). For the next financial year, analysts expect that the company will report earnings of ($1.60) per share, with EPS estimates ranging from ($1.94) to ($1.38). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Nightstar Therapeutics.
Nightstar Therapeutics (NASDAQ:NITE) last posted its quarterly earnings data on Monday, August 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.12.
Several brokerages recently weighed in on NITE. Leerink Swann increased their target price on Nightstar Therapeutics from $30.00 to $35.00 and gave the stock a “positive” rating in a research report on Monday, September 24th. BMO Capital Markets set a $41.00 target price on Nightstar Therapeutics and gave the stock a “buy” rating in a research report on Monday, September 24th. Mizuho increased their target price on Nightstar Therapeutics to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, September 4th. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Nightstar Therapeutics in a research report on Tuesday, September 25th. Finally, Janney Montgomery Scott began coverage on Nightstar Therapeutics in a research report on Wednesday, August 22nd. They issued a “buy” rating and a $34.00 target price on the stock. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $33.25.
Shares of NITE traded up $0.17 during trading hours on Friday, hitting $14.19. The stock had a trading volume of 162,252 shares, compared to its average volume of 74,674. The firm has a market capitalization of $574.08 million and a P/E ratio of -8.71. Nightstar Therapeutics has a 12-month low of $10.01 and a 12-month high of $29.55.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Redmile Group LLC increased its position in shares of Nightstar Therapeutics by 0.9% during the second quarter. Redmile Group LLC now owns 1,785,446 shares of the company’s stock worth $28,567,000 after acquiring an additional 16,500 shares during the last quarter. Partner Fund Management L.P. grew its stake in Nightstar Therapeutics by 0.7% in the second quarter. Partner Fund Management L.P. now owns 1,016,980 shares of the company’s stock worth $16,272,000 after purchasing an additional 7,007 shares in the last quarter. Woodford Investment Management Ltd acquired a new position in Nightstar Therapeutics in the second quarter worth about $5,024,000. Millennium Management LLC acquired a new position in Nightstar Therapeutics in the first quarter worth about $507,000. Finally, Stanley Laman Group Ltd. acquired a new position in Nightstar Therapeutics in the second quarter worth about $195,000. 28.62% of the stock is currently owned by institutional investors and hedge funds.
About Nightstar Therapeutics
Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy.
See Also: Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.